- Clinical trial sponsors and clinical supply vendors must fully consider all attributes of their supply chains to ensure continuity of supply post-Brexit. This whitepaper outlines many questions that sponsors and vendors alike should ask
Learn how clinical development technologies and advanced analytics navigate sponsors through the challenges of patient scarcity to transform precision oncology research.
The reasons behind the physician monitors’ reluctance, and what technology needs to offer to convince monitors their work can be more efficient — quickly detecting safety signals and speeding time to submission.
What are the things that high-performing clinical research sites do that make sponsors return to them again and again?
Insights on how to avoid startup delays, issues executing the clinical trial, or problems with making payments to sites.
How to bring efficiency back to the review process and to ensure that investigators are spending their time where it matters most, with the study participants.
Six things that high-performing clinical research sites do that make sponsors return to them again and again.
Increasingly central in the course of drug development is the inclusion of observational studies, including registries, which provide insights missing from traditional interventional studies.
This white paper discusses the role of the pharmacy in a modern day Phase I clinical research unit and its role in understanding the safety and pharmacology of a drug before Phase II can begin.
In the first annual Patient Adherence Influence Report, Adheris Health and inVentiv Health Consulting set out to understand the most influential factors driving patient adherence or non-adherence and to answer the question: Will the patient cross the finish line at the retail pharmacy, or will he or she walk away?
|
|
|
|
|
|
|
|
|